Pre- and post-chemotherapy spermatogenesis in male patients with malignant bone and soft tissue tumors
Introduction: Malignant bone and soft tissue tumors, commonly called sarcomas, predominantly originate in bone and soft tissues and typically affect individuals at a younger age. Following the resection of the primary tumor, treatment often necessitates radiation therapy and gonadotoxic chemotherapy...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1324339/full |
| _version_ | 1797403376013541376 |
|---|---|
| author | Teppei Takeshima Noboru Mimura Shun Aoki Tomoki Saito Tomoki Saito Jurii Karibe Jurii Karibe Kimitsugu Usui Kimitsugu Usui Shinnosuke Kuroda Shinnosuke Kuroda Mitsuru Komeya Mitsuru Komeya Yasushi Yumura |
| author_facet | Teppei Takeshima Noboru Mimura Shun Aoki Tomoki Saito Tomoki Saito Jurii Karibe Jurii Karibe Kimitsugu Usui Kimitsugu Usui Shinnosuke Kuroda Shinnosuke Kuroda Mitsuru Komeya Mitsuru Komeya Yasushi Yumura |
| author_sort | Teppei Takeshima |
| collection | DOAJ |
| description | Introduction: Malignant bone and soft tissue tumors, commonly called sarcomas, predominantly originate in bone and soft tissues and typically affect individuals at a younger age. Following the resection of the primary tumor, treatment often necessitates radiation therapy and gonadotoxic chemotherapy, the specifics of which depend on the disease’s stage Conversely, there is a notable concern regarding the potential loss of fertility due to these treatments. Consequently, it is recommended that men consider sperm cryopreservation before initiating treatment. This study aims to assess spermatogenesis in male patients diagnosed with malignant bone and soft tissue tumors before and after chemotherapy.Methods: This study involved 34 male patients diagnosed with malignant bone and soft tissue tumors and subsequently underwent sperm cryopreservation before initiating treatment. Medical records included details about the primary disease, age, marital status at presentation, semen analysis results, treatment regimen and number of courses, post-treatment semen analysis, renewal status and outcomes.Results: The mean age at the time of sperm cryopreservation was 22.8 years. The median semen volume was 2.5 mL, sperm concentration was 32.6 million/ml, and sperm motility was 38.5%. Following chemotherapy, semen analysis was conducted on 12 patients, with ifosfamide being the predominant drug used in all cases. Among these 12 patients, eight retained viable spermatozoa, and two successfully achieved spontaneous pregnancies resulting in live births. In one of the remaining four cases where no sperm were detected in ejaculate, a live birth was achieved through intracytoplasmic sperm injection using cryopreserved sperm.Discussion: While ifosfamide, the primary chemotherapy drug for patients with malignant bone and soft tissue tumors, was associated with severe impairments in spermatogenesis, recovery of spermatogenesis was observed in many cases. However, there were instances of prolonged azoospermia. Even in such cases, assisted reproduction using cryopreserved sperm remained viable for achieving parenthood. In light of these findings, offering patients the opportunity for fertility preservation is advisable. |
| first_indexed | 2024-03-09T02:38:12Z |
| format | Article |
| id | doaj.art-2a4e68b8ce2b4bafaa11e95186850595 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-09T02:38:12Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-2a4e68b8ce2b4bafaa11e951868505952023-12-06T08:08:27ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-12-011410.3389/fphar.2023.13243391324339Pre- and post-chemotherapy spermatogenesis in male patients with malignant bone and soft tissue tumorsTeppei Takeshima0Noboru Mimura1Shun Aoki2Tomoki Saito3Tomoki Saito4Jurii Karibe5Jurii Karibe6Kimitsugu Usui7Kimitsugu Usui8Shinnosuke Kuroda9Shinnosuke Kuroda10Mitsuru Komeya11Mitsuru Komeya12Yasushi Yumura13Department of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Kanagawa, JapanDepartment of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Kanagawa, JapanDepartment of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Kanagawa, JapanDepartment of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Kanagawa, JapanDepartment of Urology, Saiseikai Yokohama City Nanbu Hospital, Yokohama, Kanagawa, JapanDepartment of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Kanagawa, JapanDepartment of Urology, Sagami Rinkan Hospital, Sagamihara, Kanagawa, JapanDepartment of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Kanagawa, JapanDepartment of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, JapanDepartment of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Kanagawa, JapanGlickman Kidney and Urological Institute, Cleveland Clinic Foundation, Cleveland, OH, United StatesDepartment of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Kanagawa, JapanDepartment of Urology, Yokohama City University Hospital, Yokohama, Kanagawa, JapanDepartment of Urology, Reproduction Center, Yokohama City University Medical Center, Yokohama, Kanagawa, JapanIntroduction: Malignant bone and soft tissue tumors, commonly called sarcomas, predominantly originate in bone and soft tissues and typically affect individuals at a younger age. Following the resection of the primary tumor, treatment often necessitates radiation therapy and gonadotoxic chemotherapy, the specifics of which depend on the disease’s stage Conversely, there is a notable concern regarding the potential loss of fertility due to these treatments. Consequently, it is recommended that men consider sperm cryopreservation before initiating treatment. This study aims to assess spermatogenesis in male patients diagnosed with malignant bone and soft tissue tumors before and after chemotherapy.Methods: This study involved 34 male patients diagnosed with malignant bone and soft tissue tumors and subsequently underwent sperm cryopreservation before initiating treatment. Medical records included details about the primary disease, age, marital status at presentation, semen analysis results, treatment regimen and number of courses, post-treatment semen analysis, renewal status and outcomes.Results: The mean age at the time of sperm cryopreservation was 22.8 years. The median semen volume was 2.5 mL, sperm concentration was 32.6 million/ml, and sperm motility was 38.5%. Following chemotherapy, semen analysis was conducted on 12 patients, with ifosfamide being the predominant drug used in all cases. Among these 12 patients, eight retained viable spermatozoa, and two successfully achieved spontaneous pregnancies resulting in live births. In one of the remaining four cases where no sperm were detected in ejaculate, a live birth was achieved through intracytoplasmic sperm injection using cryopreserved sperm.Discussion: While ifosfamide, the primary chemotherapy drug for patients with malignant bone and soft tissue tumors, was associated with severe impairments in spermatogenesis, recovery of spermatogenesis was observed in many cases. However, there were instances of prolonged azoospermia. Even in such cases, assisted reproduction using cryopreserved sperm remained viable for achieving parenthood. In light of these findings, offering patients the opportunity for fertility preservation is advisable.https://www.frontiersin.org/articles/10.3389/fphar.2023.1324339/fullspermsperm cryopreservationmalignant bone tumormalignant soft tissue tumorsarcomafertility preservation |
| spellingShingle | Teppei Takeshima Noboru Mimura Shun Aoki Tomoki Saito Tomoki Saito Jurii Karibe Jurii Karibe Kimitsugu Usui Kimitsugu Usui Shinnosuke Kuroda Shinnosuke Kuroda Mitsuru Komeya Mitsuru Komeya Yasushi Yumura Pre- and post-chemotherapy spermatogenesis in male patients with malignant bone and soft tissue tumors Frontiers in Pharmacology sperm sperm cryopreservation malignant bone tumor malignant soft tissue tumor sarcoma fertility preservation |
| title | Pre- and post-chemotherapy spermatogenesis in male patients with malignant bone and soft tissue tumors |
| title_full | Pre- and post-chemotherapy spermatogenesis in male patients with malignant bone and soft tissue tumors |
| title_fullStr | Pre- and post-chemotherapy spermatogenesis in male patients with malignant bone and soft tissue tumors |
| title_full_unstemmed | Pre- and post-chemotherapy spermatogenesis in male patients with malignant bone and soft tissue tumors |
| title_short | Pre- and post-chemotherapy spermatogenesis in male patients with malignant bone and soft tissue tumors |
| title_sort | pre and post chemotherapy spermatogenesis in male patients with malignant bone and soft tissue tumors |
| topic | sperm sperm cryopreservation malignant bone tumor malignant soft tissue tumor sarcoma fertility preservation |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1324339/full |
| work_keys_str_mv | AT teppeitakeshima preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors AT noborumimura preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors AT shunaoki preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors AT tomokisaito preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors AT tomokisaito preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors AT juriikaribe preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors AT juriikaribe preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors AT kimitsuguusui preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors AT kimitsuguusui preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors AT shinnosukekuroda preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors AT shinnosukekuroda preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors AT mitsurukomeya preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors AT mitsurukomeya preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors AT yasushiyumura preandpostchemotherapyspermatogenesisinmalepatientswithmalignantboneandsofttissuetumors |